Infliximab for induction and maintenance therapy for ulcerative colitis.

By P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. Hanauer, G. Lichtenstein and 4 more. New England Journal of Medicine, 2005

3,569 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/16d9d02c5357ac4a70c0921861490c23aea6f561

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. W. Sandborn
2. Stefan Schreiber
3. J. Colombel
4. S. Hanauer
5. P. Rutgeerts
6. Ashwin N. Ananthakrishnan
7. Markus F. Neurath

In Immunology

1. Stefan Schreiber
2. W. Sandborn
3. S. Hanauer

In Rheumatology

1. Stefan Schreiber
2. W. Sandborn
3. J. Colombel
4. Markus F. Neurath

Citations in the corpus

• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011, background): “in an attempt to increase treatment options and improve clinical outcomes, but only the chimeric monoclonal anti-tumour necrosis factor α (TNFα) antibody, infliximab, has been shown to induce and maintain remission in patients with moderate to severe ulcerative colitis.”
• Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, neutral): “, 1994b) anti-TNF (approved for UC and CD) (Hanauer et al., 2002; Rutgeerts et al., 2005; Targan et al., 1997) TNFSF15, TNFSF8 LTBR, TNFRSF1A”
• Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014, background): “2) 18 to <65 y, n (%) 76 (96) 65 y, n (%) 3 (4) Female, n (%) 46 (58) Prior immunomodulatory therapy, n (%) 8 (10.”